In Section C, members will acquire ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until illness progression or the participants are unable to tolerate the study drugs. after which you can promote H3K27Ac at this location. Chromatin hyperacetylation could enhance https://judahalxhs.get-blogging.com/32443232/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml